Keywords: immtech, licenses, pafuramidine, par, pharmaceuticals, granted, exclusive

Immtech licenses pafuramidine to Par

Article | 18 June 2007

Immtech Pharmaceuticals has granted an exclusive license to fellow USA-based Par Pharmaceutical to commercialize its lead oral drug, pafuramidine maleate, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing